Nov 01, 2022 / NTS GMT
Matts Johansen - Aker BioMarine ASA - CEO
Good morning, and welcome to the presentation of Aker BioMarine's third-quarter results, where myself and CFO, Katrine Klaveness, will take you through the highlights and the key numbers from the quarter. After the presentation, we will host a Q&A session, and you can already now start to type in your questions to [email protected].
For the third quarter, Aker BioMarine delivered 10% growth on revenue and 28% growth on EBITDA. And for the second quarter in a row, we delivered black numbers on the bottom line with $5 million of net profit. We had a particularly strong harvesting quarter in the third quarter; and year to date, we have produced more than 50,000 tons of product, which is 23% more than what we have done at the same time last year.
On the sales side, we have growth across all segments, from Superba to qrill and in brands. And also in the third quarter, we signed the first commercial agreement for our new innovation Lysoveta, the new molecule that takes omega-3s across the blood brain barrier.
When we look at revenues, the
Q3 2022 Aker Biomarine ASA Earnings Call Transcript
Mar 01, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers